Related references
Note: Only part of the references are listed.Role of Immunotherapy in Breast Cancer
Saya L. Jacob et al.
JCO ONCOLOGY PRACTICE (2023)
Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment
Toru Hanamura et al.
BREAST CANCER RESEARCH (2023)
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
Carmine Valenza et al.
CANCERS (2023)
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
Jonathan M. Kocarnik et al.
JAMA ONCOLOGY (2022)
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
Denise M. Wolf et al.
CANCER CELL (2022)
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Khalid El Bairi et al.
NPJ BREAST CANCER (2021)
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
Meenakshi Anurag et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer
Hyun Lee et al.
ANTICANCER RESEARCH (2020)
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
C. Criscitiello et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients
Werner Schroth et al.
CLINICAL CANCER RESEARCH (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis
Zhao-hua Gao et al.
BMC CANCER (2020)
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial
Cornelia Kolberg-Liedtke et al.
BREAST CANCER RESEARCH (2020)
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
Yukie Fujimoto et al.
BREAST CANCER (2019)
SEOM clinical guidelines in early stage breast cancer (2018)
F. Ayala de la Pena et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
Marcelo Sobral-Leite et al.
BREAST CANCER RESEARCH (2019)
Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
Sung Gwe Ahn et al.
BMC CANCER (2018)
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer
Juan Miguel Cejalvo et al.
CANCER TREATMENT REVIEWS (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F. Klauschen et al.
SEMINARS IN CANCER BIOLOGY (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Anita K. Dunbier et al.
CLINICAL CANCER RESEARCH (2013)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Share Paper
